From the academyGuidelines of care for the management of primary cutaneous melanoma
Key words
Abbreviations used
Cited by (0)
Funding sources: None.
Disclosure: The following information represents the authors' disclosed relationships with industry during guideline development. Relevant relationships requiring recusal for drafting of guideline recommendations and content by Work Group members are noted where applicable for each author. Hensin Tsao, MD, served as an advisory board member for Lubax and Epiphany Dermatology, receiving honoraria; in another role with Journal Watch Dermatology, receiving honoraria; and as a principal investigator for Relay Therapuetics, receiving grant funding. Clara Curiel-Lewandrowski, MD, served as a founder of DermSpectra LLC, receiving stock, and as a consultant for Amgen, receiving honoraria; she has a first-degree relative who received honoraria from Amendia. David E. Elder, MBChB, served as a consultant for SciBase and Myriad Genetics, receiving honoraria; he was recused from drafting recommendations related to adjunctive pathology tests for equivocal nevi. Jeffrey E. Gershenwald, MD, served as an advisory board member for Merck, Syndax Pharmaceuticals, and Castle Biosciences, receiving fees; and in another role for Mercator Therapeutics, receiving patent royalties; he was recused from drafting recommendations related to prognostic molecular tests. Jane M. Grant-Kels, MD, was a stockholder for Melafind; she was recused from drafting recommendations related to diagnostic imaging. Allan C. Halpern, MD, served as a consultant for Canfield Scientific, Inc, DermTech, International Janssen Research and Development LLC, and SciBase, receiving other financial benefits; as a member of the advisory board for Lucid, Inc, and Caliber Imaging and Diagnostics, receiving other financial benefits; and in another role for Quintiles Pharma, receiving other financial benefits. Dr Halpern was recused from drafting recommendations related to diagnostic imaging. Arthur J. Sober, MD, served as a principal investigator for MelaSciences, receiving grants/research funding; he was recused from drafting recommendations related to diagnostic imaging. John A. Thompson, MD, served as a consultant for Eisai Pharmaceuticals and Genentech, receiving honoraria; and as a member of the data safety monitoring board for Celldex, receiving honoraria. Oliver J. Wisco, DO, served as a consultant for MiMedx Group, Inc, and ClearPath Diagnostics, receiving fees. Dr Wisco was also a stockholder for MiMedx Group, Inc; he was recused from drafting recommendations on topic areas related to ClearPath products. Shasa Hu, MD, served as an advisory board member for Cosmetic Dermatology, receiving fees. Susan M. Swetter, MD, Christopher K. Bichakjian, MD, Valerie Guild, MS, MBA, Timothy M. Johnson, MD, Samantha Wyatt, MD, and Toyin Lamina, PhD, have no conflicts of interest to disclose.
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
Reprint requests: [email protected].